跳至主要内容
临床试验/NL-OMON48592
NL-OMON48592已完成2 期

Guselkumab for hidradenitis suppurativa, a mode of action study. - HiGUS trial

niversitair Medisch Centrum0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Adult (* 18 years of age) male or female patients with moderate to severe HS (i.e. a PGA of 3 or more) with a treatment history of at least one systemic anti-in*ammatory / immunosuppressive agent; HS diagnosis of at least 1 year; minimum of two anatomical locations with HS lesions and a minimum of 4 active abscesses and/or inflammatory nodules (AN).

排除标准

  • Contra-indication for guselkumab; previous use of guselkumab; use of treatment with biologics or any immunosuppressives for HS in the last 3 months prior to randomization; presence of other uncontrolled major disease; pregnant or lactating women.

研究者

发起方
niversitair Medisch Centrum

相似试验